***Background.*** A quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM) is immunogenic in 4-dose infant or 2-dose toddler schedules. We report on persistence of bactericidal antibodies in each group at 60 months of age, and responses 1 month after a booster.

***Methods.*** In this phase IIIb, multi-center, open-label, controlled study (clinicaltrials.gov NCT01148017), subjects vaccinated as infants or toddlers were re-evaluated at 60 months of age, with age-matched vaccine-naïve controls. Bactericidal antibodies with human complement (hSBA) measured before and 1 month after booster are expressed as geometric mean titers (GMT) and proportions with seroprotective titers (≥ 8).

***Results.*** We enrolled 131 infant- and 54 toddler-vaccinated subjects, and 50 controls. At 60 months titers had waned, but GMTs were higher in toddler-vaccinated than in infant-vaccinated, and both were higher than controls. Immune responses to another dose of MenACWY-CRM were higher in both prevaccinated groups, who displayed anamnestic responses. GMTs for serogroups A, C, W, and Y were 177, 206, 1706 and 1135 in infant-vaccinated, 356, 723, 1960 and 1187 in toddler-vaccinated, and 47, 44, 37 and 18 in controls, respectively; 96--100% developed titers ≥ 8 compared with 73--89% of controls (table).

                    Percentages with hSBA ≥ 8 \[95%CI\]                                                                                       
  ----------------- ------------------------------------- --------------------- ------------------- --------------------- ------------------- -------------------
  *n/N*             *7/122*                               *111/115*             *12/48*             *45/45*               *1/45*              *39/45*
  **Serogroup A**   **6** \[2, 11\]                       **97** \[91, 99\]     **25** \[14, 40\]   **100** \[92, 100\]   **2** \[0.1, 12\]   **87** \[73, 95\]
  *n/N*             *32/122*                              *109/114*             *26/48*             *44/44*               *10/45*             *38/45*
  **Serogroup C**   **26** \[19, 35\]                     **96** \[90, 99\]     **54** \[39, 69\]   **100** \[92, 100\]   **22** \[11, 37\]   **84** \[71, 94\]
  *n/N*             *82/120*                              *103/103*             *38/47*             *42/42*               *18/45*             *39/44*
  **Serogroup W**   **68** \[59, 77\]                     **100** \[96, 100\]   **81** \[67, 91\]   **100** \[92, 100\]   **40** \[26, 56\]   **89** \[75, 96\]
  *n/N*             *68/121*                              *110/110*             *35/48*             *44/44*               *11/44*             *32/44*
  **Serogroup Y**   **56** \[47, 65\]                     **100** \[97, 100\]   **73** \[58, 85\]   **100** \[92, 100\]   **25** \[13, 40\]   **73** \[57, 85\]

MenACWY-CRM vaccination at 60 months caused mainly mild or moderate solicited reactions in 62% of infant, 64% of toddler and 76% of control groups. No SAEs were reported.

***Conclusion.*** Modest antibody persistence after infant or toddler vaccination with MenACWY-CRM was observed at 60 months of age with a robust booster effect and high seroprotection rates postvaccination.
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